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Abstract
Background: Human infection with avian influenza A virus (H7N9) was first reported in China in March 2013. Since
then, hundreds of cases have been confirmed showing severe symptoms with a high mortality rate. The virus was
transmitted from avian species to humans and has spread to many neighboring areas, raising serious concerns over
its pandemic potential. Towards containing the disease, the goal of this study is to prepare a virus-like particle (VLP)
that consists of hemagglutinin (HA), neuraminidase (NA) and matrix protein 1 (M1) derived from the human isolate
A/Taiwan/S02076/2013(H7N9) for potential vaccine development.
Results: Full length HA, NA, and M1 protein genes were cloned and expressed using a baculoviral expression
system, and the VLPs were generated by co-infecting insect cells with three respective recombinant baculoviruses.
Nanoparticle tracking analysis and transmission electron microscopy were applied to verify the VLPs’ structure and
antigenicity, and the multiplicity of infection of the recombinant baculoviruses was adjusted to achieve the highest
hemagglutination activity. In animal experiments, BALB/c mice and specific-pathogen-free chickens receiving the
VLP immunization showed elevated hemagglutination inhibition serum titer and antibodies against NA and M1
proteins. In addition, examination of cellular immunity showed the VLP-immunized mice and chickens exhibited an
increased splenic antigen-specific cytokines production.
Conclusions: The H7N9 VLPs possess desirable immunogenicity in vivo and may serve as a candidate for vaccine
development against avian influenza A (H7N9) infection.
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Background
Human infection with avian influenza A (H7N9) was
first reported in China in March 2013, and since then
hundreds of human cases have been confirmed. The dis-
ease is associated severe respiratory illness, and the high
mortality rate has garnered increasing attention globally
[1, 2]. The ability of the virus to transmit from avian
species to humans has contributed to its spread to
neighbouring areas of China and raises serious concerns
over its pandemic potential, particularly in areas with
poultry farming industry. With the growing need for
countermeasures against the infectious threat, develop-
ment of effective vaccines is of increasing importance. In
addition to ongoing efforts on developing human vac-
cines against avian influenza virus A/H7N9, formula-
tions that can effectively mount immunity in avian
models are of significant public health and economic
considerations as they may contain interspecies trans-
missions and improve overall poultry health. With the
aim to prepare a vaccine candidate towards both human
and avian applications, we prepared and characterized
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an A/H7N9-mimicking virus-like particle (VLP). The
immune-potentiating effect of the VLP was evaluated in
both a mammalian (mouse) and an avian (chicken)
model to examine the particles’ potential as an anti-viral
vaccine.
Similar to other influenza A viruses, H7N9 viral cap-
sids are comprised of three primary proteins, including
hemagglutinin (HA), neuraminidase (NA), and matrix
protein 1 (M1). Upon co-expression, these three proteins
self-assemble into nanoparticles, which are responsible
for packaging viral genomes for disease transmission [3].
Previously, VLPs, which are non-infectious particles de-
void of any viral genes, have been shown to induce pro-
tective immunity against influenza and other viral
diseases [4–9]. The VLPs’ morphological and antigenic
semblance to native virions facilitate effective immune
processing, making them a compelling alternative to free
viral antigens as vaccine candidates. In the present study,
VLPs consisting of hemagglutinin (HA), neuraminidase
(NA) and matrix protein 1 (M1) derived from the hu-
man isolate A/Taiwan/S02076/2013 (H7N9) were pre-
pared for vaccine development. A combinatorial
baculoviral system was applied to generate VLPs co-
expressing the three viral proteins, which have been rec-
ognized as major antigenic targets of the H7N9 virus
[10, 11]. The resulting VLPs were assayed for their
hemagglutination activity. Nanoparticle tracking analysis
was applied to verify the size, surface charge, and con-
centration of the VLPs, and transmission electron mi-
croscopy following immunogold staining was performed
to validate the VLPs’ multi-antigenic nature. A mouse
model was first used to validate the VLPs’ immunogen-
icity, and a particular emphasis was placed on the
humoral and cellular immune responses in a chicken
model following vaccination with either VLPs or free
protein antigens. Results observed from the study offer
hope that the formulation may find applications in both
clinical and agricultural settings.
Methods
Cells and recombinant baculoviruses
S. frugiperda Sf9 (ATCC CRL-1711) and Sf21 (Invitro-
gen, Carlsbad, CA) insect cells were maintained as
suspension cultures in Grace’s medium (Invitrogen,
Carlsbad, CA) and supplemented with 10% FBS
(Thermo Scientific, Rockford, IL) and 1% P/S/A antibi-
otics (Biological Industries, Beit-Haemek, Israel).
Recombinant baculoviruses were prepared by using
the Bac-to-Bac baculovirus expression system (Invitro-
gen). Briefly, three separate recombinant plasmids were
constructed by inserting full HA, NA, and M1 genes of
A/Taiwan/S02076/2013(H7N9) (accession no. KF018045,
KF018047, and KF018048) into the pFastBac-1 vector
using primers listed in Table 1. The recombinant
pFastBac-1 shuttle vectors were then transposed to the
bacmid in E. coli strain DH10Bac, and recombinant bac-
mid was purified using the HiPure Plasmid Midiprep kit
(Invitrogen). Sf9 cells were used for transfection with the
recombinant bacmid. Right before transfection, 8 μl of
the Cellfectin II Reagent (Invitrogen) was diluted in
100 μl of Grace’s medium (without antibiotics and
serum), and 1 μg of bacmid DNA was diluted in 100 μl
of Grace’s medium (without antibiotics and serum). Sub-
sequently, the diluted bacmid DNA and diluted Cellfec-
tin II were combined and incubated for 30 min at room
temperature. The DNA-lipid mixture was then added
onto the cells dropwise and incubated at 27 °C for 4 h.
Following removal of transfection mixture, fresh cell
medium was added to the cells. After 72 h, recombinant
baculoviruses were harvested from the supernatant and
designated as rBac-H7, rBac-N9, and rBac-M1, respect-
ively. The recombinant baculoviruses were subsequently
amplified in Sf9 cells, and virus titers were determined
by plaque assays in Sf21 cells.
Immunofluorescence assay (IFA)
Sf9 cells were infected with rBac-H7, rBac-N9, and rBac-
M1 at a multiplicity of infection (MOI) of 2. Three days
later, the monolayer of cells was washed and fixed with
80% acetone at −20 °C for 20 min. Rabbit polyclonal
antibody against H7/HA peptide (Sino Biological,
Beijing, China), rabbit polyclonal antibody against N9/
NA peptide (ProSci, Poway, CA), and mouse polyclonal
antibody against a recombinant M1 protein were applied
at 1:10,000, 1:2,000, and 1:1,000 dilutions respectively
and incubated for 1 h. After PBS wash, cells were further
Table 1 Primer sets used in the plasmid construction
Primer Target aSequence Sense Product
HA-SpeI-F H7/HA GCCTAGACTAGTATGAACACTCAAATCCTG + 1683 bp
HA-KpnI-R H7/HA GCACGGTACCTTATATACAAATAGTGCACC -
NA-BamHI-F N9/NA TAGATCGGATCCATGAATCCAAATCAGAAG + 1398 bp
NA-KpnI-R N9/NA GATCGGTACCTTAGAGGAAGTACTCTATTT -
M1-BamHI-F M1 TAGATCGGATCCATGAGTCTTCTAACCGAG + 759 bp
M1-HindIII-R M1 AGCTAAGCTTTCACTTGAACCGCTGCAGTT -
aThe restriction sites are bold
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incubated with FITC-conjugated anti-rabbit or anti-
mouse IgG (Jackson ImmunoResearch Laboratories,
West Grove, PA). Fluorescence signal was observed
under a fluorescence microscope.
Production and purification of H7N9 recombinant
proteins and VLPs
H7, N9 and M1 recombinant proteins were harvested
from lysed Sf9 cells that were infected with rBac-H7,
rBac-N9, or rBac-M1 (MOI = 2). After 72 h, the cells
were washed and lysed with the I-PER insect cell protein
extraction reagent (Thermo Scientific). Recombinant
proteins were purified using the Glycoprotein Isolation
Kit, ConA (Thermo Scientific) according to the manu-
facturer’s instructions.
H7N9 VLP was harvested and purified from the cul-
ture supernatant of Sf9 cells co-infected with rBac-H7,
rBac-N9, or rBac-M1. Briefly, 72 h after co-infection, the
cell culture supernatant was centrifuged at 3,000 × g for
20 min, and the VLPs were pelleted by centrifugation at
70,000 × g for 2 h at 4 °C. The pellet was resuspended in
TEN buffer (10 mM Tris-base, 1 mM EDTA, and
100 mM NaCl). The resultant solution was layered onto
a sucrose gradient solution (20–50% in TEN buffer) and
centrifuged at 100,000 × g for 2 h. Particles from each
gradient fraction were separately collected for the HA
test and TEM analysis (described below), and the frac-
tions demonstrating the highest HA activity and appro-
priate morphology were pooled as purified VLPs.
The protein concentration was quantified by the Brad-
ford protein assay (Bio-Rad, Richmond, CA) according
to the manufacturer’s recommendations. H7N9 recom-
binant proteins and VLPs were analyzed by 10% SDS-
PAGE, and probed with anti-H7/HA, anti-N9/NA, and
anti-M1 antibodies in the IFA section. To detect the
protein signals, the membranes were incubated with
HRP-conjugated anti-rabbit or anti-mouse IgG (Jackson
ImmunoResearch Laboratories) at a 1:2,000 dilution for
another hour and developed using ECL Western blotting
detection kit (Bio-rad).
Immunogold labeling of VLPs
Purified VLPs were absorbed onto a plasma-discharged
copper grid for 2 min and fixed with 4% paraformalde-
hyde for 5 min. After PBS washes and blocking with 1%
BSA (Sigma, St. Louis, MO), the grid was incubated with
either anti-H7/HA or N9/NA antibodies (1:200) for 1 h
followed by incubation with 6 nm gold-conjugated goat
anti-rabbit antibodies (1:20) (Jackson ImmunoResearch
Laboratories). After PBS washes, 2% phosphotungstic
acid was applied for negative staining. Particles were ob-
served under a transmission electron microscope (TEM)
(JEOL JEM-1400).
Nanoparticle tracking analysis
Particle concentration, size distribution, and surface
zeta potential of the expressed H7N9 VLPs were mea-
sured by nanoparticle tracking analysis using Nano-
Sight NS-500 (Malvern Instruments Inc., UK) based
on the manufacturer’s instructions. The purified influ-
enza virus A/PuertoRico/8/34(H1N1) [12] was in-
cluded as a reference.
Optimization of co-infection of recombinant
baculoviruses
Four different conditions of co-infection were tested.
rBac-HA (at an MOI of 2, 3.6, 4, 5), rBac-NA (at an
MOI of 2, 5, 5, 6), and rBac-M1 (at an MOI of 2, 5, 10,
20) were combined respectively and used for co-
infection in Sf9 cells. After 72 h, the cell culture super-
natant was centrifuged at 3,000 × g for 20 min, and the
VLPs were pelleted by centrifugation at 70,000 × g for
2 h at 4 °C. The pellet was resuspended in TEN buffer,
and the resultant solution was layered using a sucrose
gradient solution (20–50% in TEN buffer) via centrifuga-
tion at 100,000 × g for 2 h. Particles from each gradient
fraction were separately collected for a hemagglutination
test (described below).
Mice and chickens immunization
Female 6-week-old BALB/c mice were purchased from
BioLASCO (Taipei, Taiwan). Two-week-old specific-
pathogen-free (SPF) chickens were obtained from JD-
SPF Biotech (Miaoli, Taiwan). Animals were randomly
divided into different experimental groups (n = 6 per
group), receiving H7N9 VLPs, HA/NA/M1 free proteins
(only for chickens), or PBS. Briefly, 10 μg of VLPs or
pre-mixed HA/NA/M1 proteins at a 1:1:1 ratio were
emulsified with the complete Freund’s adjuvant and used
for the primary immunization using an intramuscular
route. For the booster dose, the same amount of the
antigen was mixed with the incomplete Freund’s adju-
vant. Mouse serum was collected before immunization
and 14 days post-immunization (dpi), and mice were
sacrificed at 28 dpi. Chicken serum was collected before
immunization and at 14, 19, and 26 dpi, and all the
chickens were sacrificed at 40 dpi. Mice and chickens
were sacrificed by CO2 inhalation.
Hemagglutination (HA) test and hemagglutination
inhibition (HI) test
H7N9 VLPs and inactivated H7N9 virions were used as
HA antigens in this study. Inactivated H7N9 virions
were prepared as previously described [13]. HA and HI
tests were performed with standard protocols provided
by WHO [14]. Briefly, the HA activity of purified H7N9
VLPs or inactivated H7N9 virions was tested against red
blood cells (RBCs), and HA titers were recorded as the
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highest dilution exhibiting complete hemagglutination.
For the HI test, the receptor-destroying enzyme was
used for treating animal sera, and HI titers were re-
corded as the highest serum dilution exhibiting complete
hemagglutination inhibition.
Antigen-specific cytokine expression analysis
Mice spleens were harvested at 28 dpi, and splenocytes
were isolated for intracellular cytokine staining assays.
Briefly, spleens were minced and passed through 70-μm
cell strainers (Corning) to obtain single-cell suspensions.
RBCs were lysed using an RBC lysis buffer (eBios-
ciences), and cells were resuspended in RPMI 1640
medium (Gibco, Grand Island, NY) containing 10% FBS.
Viable cells were determined by trypan blue staining.
106 splenocytes were plated in 96-well U-bottom plates
(Corning) and were either mock-stimulated or stimu-
lated with 10 μg of H7N9 VLPs in the presence of bre-
feldin A (GolgiPlug, BD Biosciences, San Diego, CA) for
5 h at 37 °C. Cells were then washed, incubated with
2.4G2 antibody, and labeled with anti-CD3e-FITC, anti-
CD4-PerCP-Cy5.5, and anti-CD8a-PerCP-Cy5.5. The
cells were then fixed and permeabilized using a Cytofix/
Cytoperm Kit (BD Biosciences) and stained with anti-
IL4-PE, anti-IFNγ-APC and anti-TNF-PE. All antibodies
for mouse experiments were purchased from BD Biosci-
ences. Samples were read on the BD FACSCalibur and
analyzed using FlowJo software (Tree Star, CA).
Chicken spleens were harvested at 40 dpi, and spleno-
cytes were isolated and stimulated with H7N9 VLPs in
the presence of brefeldin A as described above. For the
flow cytometric analysis, cells were washed and labeled
with anti-chicken CD4 or CD8 antibodies (AbD Serotec,
Raleigh, NC). The amount of CD4+ or CD8+ T cells
gated on 2 x 104 lymphocytes was determined. For the
quantification of cytokine expression, the stimulated
splenocytes were lysed, and total RNA was isolated by
TriSolution reagent (GeneMark, Taipei, Taiwan). Real-
time reverse transcription polymerase chain reaction
(RT-PCR) was performed using iScript (Bio-rad) and iQ
SYBR Green Supermix Kit (Bio-rad) with previously de-
scribed primers for chicken IL-4, IFN-γ and GAPDH
[15]. Melting curve analysis following real-time PCR was
conducted to verify the specificity for each primer set.
All obtained Ct values were normalized to GAPDH. The
relative expression of chicken IL-4 and IFN-γ (fold
change of PBS-vaccinated control) was determined by a
2-ΔΔCt method [16].
Enzyme-linked immunosorbent assay (ELISA)
An amount of 100 ng purified NA or M1 protein was
coated onto the flat-bottomed 96 well microplate (Nunc,
Roskilde, Denmark) overnight at room temperature.
After blocking with 5% skim milk (BD Difco, Sparks,
MD), the test chicken sera were serially diluted and in-
cubated for 1 h. Following washes, 100 μl of peroxidase-
conjugated goat anti-chicken IgY (H + L) (Jackson
ImmunoResearch Laboratories) diluted 1:2,000 in block-
ing buffer was dispensed into each well and incubated
for another 1 h. After additional three washes, the wells
were incubated with 100 μl of SureBlue Reserve TMB
Microwell Peroxidase Substrate (KPL, Gaithersburg,
MD), and color was allowed to develop in the dark for
10 min. The reaction was stopped by the addition of
100 μl of TMB stop solution (KPL). All the incubation
steps were performed at room temperature. The optical
density (OD) at 450 nm was read using an automated
plate reader (Thermo Scientific).
Statistical analyses
Data were analyzed by unpaired t tests or ANOVA
followed by Dunnett’s multiple comparison tests using
GraphPad Prism (GraphPad Software, San Diego, CA).
The p values smaller than 0.05 were considered
significant.
Results
Production of H7N9 VLPs
The full length HA (1,683 nt), NA (1,398 nt), and M1
(759 nt) genes of A/Taiwan/S02076/2013(H7N9) were
cloned into three separate recombinant baculoviruses.
As indicated in Fig. 1, Sf9 cells were co-infected by the
three recombinant baculoviruses, rBac-H7, rBac-N9,
rBac-M1, to generate H7N9 VLPs. The titer of each re-
combinant baculovirus was determined as 6 × 106
plaque-forming unit (PFU)/mL, 3 × 107 PFU/mL, and
1 × 108 PFU/mL, respectively, by plaque assays (Fig. 2a,
upper panel). The expression of HA, NA, and M1 pro-
teins in Sf9 cells was identified by IFA using FITC-
labelled antigen-specific antibodies. In Sf9 cells nuclei-
stained with DAPI, FITC signal was observed in the
cytoplasm (Fig. 2a, lower panel), indicating successful
protein expression by the respective recombinant
baculovirus. In contrast, no FITC signal was observed
from the uninfected Sf9 cells following staining by any
of the antigen-specific antibodies (data not shown).
As HA is a primary protein that determines the anti-
genic signature and virulence of influenza viruses, we
applied an HA activity assay using chicken red blood
cells to optimize the co-infection condition and the VLP
collection protocol. The three recombinant baculo-
viruses of different combinations of multiplicity of infec-
tion were prepared to co-infect Sf9 cells. The culture
supernatants of the resulting co-infected Sf9 cells were
subsequently collected and purified using sucrose gradi-
ent centrifugation. Among four different combinations
of MOI, the highest HA titer (1: 28) was obtained from
the co-infection condition at an MOI of 2 for each of
Hu et al. BMC Biotechnology  (2017) 17:2 Page 4 of 12
the recombinant baculovirus. This heightened HA activ-
ity was particularly pronounced in fractions containing
30–40 wt.% of sucrose (Fig. 2b). Based on the observa-
tion, all VLPs in the remainder of the study were pre-
pared using Sf9 cells co-infected with the three
recombinant baculoviruses with an MOI of 2. Plaque as-
says were applied to ensure undetectable titer of residual
baculovirus for every batch of the VLPs.
Characterization of H7N9 VLPs
Upon collection of purified VLPs, Western blotting ana-
lysis was applied to confirm the presence of all three of
the HA (66 kDa), NA (68 kDa), and M1 (25 kDa) pro-
teins. Each protein on the VLPs was observed to be
largely identical in size to the protein from cells infected
individually by rBac-H7, rBac-N9, and rBac-M1 (Fig. 2c).
This result indicates the three proteins self-assemble
without undergoing further modifications.
To examine the formation and antigen display of
the H7N9 VLPs, immunogold staining was performed.
Under the TEM visualization, particles approximately
120 nm in diameter were observed, confirming suc-
cessful preparation of VLPs that resemble the morph-
ology of H7N9 viruses. Labeling by immunogold
further confirmed the presence of HA proteins
(Fig. 3a, left) and NA proteins (Fig. 3a, right) on the
surface of the particles. Examination by nanoparticle
tracking analysis revealed a unimodal particle size dis-
tribution for the VLPs with an average particle diam-
eter of 113.9 ± 0.6 nm, which is similar to that of a
native H1N1 virus (122.1 ± 2.9 nm) observed using
the technique (Fig. 3b). The surface charge of the
VLPs is −24 ± 0.2 mV, which is also similar to that
measured from the H1N1 virus (−37 ± 0.1 mV)
(Fig. 3c). In addition, the nanoparticle tracking ana-
lysis provided insight to the mass of each individual
VLP. Based on the observed particle concentration
and protein quantification by Bradford assay, it was
approximated that there are 1.11 × 109 particles per
1 μg of the VLPs, yielding a molecular weight of
roughly 5.42 × 108 Da per particle. Protein quantifica-
tion showed that the HA protein contributed to ap-
proximately 10% of total proteins in collected H7N9
VLPs (Additional file 1: Figure S1), translating to
~800 HA proteins per VLP. The number of HA pro-
teins per VLP is in line with the estimated number in
native virion [17]. The purified H7N9 VLPs agglutin-
ate RBCs at a minimum total protein amount of
0.098 μg (Fig. 3d), indicating proper display of the
receptor-binding domain of HA protein in the VLPs.
H7N9 VLP immunization elicited hemagglutination-
inhibition antibody response in mice
To validate the VLPs’ immunogenicity, mice were immu-
nized twice with 10 μg of the VLP (approximately 1 μg
of HA content) with a two-week interval (Fig. 4a). Blood
was collected right before each vaccination for analysis.
The level of serum HI antibody was evaluated by an HI
test. As compared to the PBS-immunization control
group, VLP-immunized mice exhibited a higher HI anti-
body response after a primary and a booster vaccination.
On day 28, the average HI antibody endpoint dilution
titer reached 1:80 and 1:160 against 4 hemagglutination
units of H7N9 VLPs and inactivated H7N9 virions
Fig. 1 A schematic diagram of H7N9 VLP expression. The genes HA, NA, and M1 were cloned into three recombinant baculoviruses, respectively.
Sf9 cells were co-infected by the three recombinant baculoviruses, and the VLPs that assembled HA, NA, and M1 were harvested in the Sf9
culture supernatant
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respectively (Fig. 4b, c). The study validates the H7N9
VLP’s ability to elicit an anti-HA humoral response in
mice.
H7N9 VLP immunization promotes virus-specific T cell
immunity in mice
To examine splenic virus-specific T cell response in
H7N9 VLP-immunized mice, intracellular cytokine
staining was conducted on the harvested splenocytes on
the day of sacrifice. In VLP-vaccinated mice, production
of IL-4 and TNF were shown to be elevated in splenic
CD4 and CD8 T cells respectively (Fig. 4d and f). Al-
though statistical significance was not reached, the mean
percentage of IFN-γ-producing CD4 and CD8 T cells in
mice spleens was observed to be greater than the control
group following VLP vaccination (Fig. 4e and g). The re-
sults suggest that the VLP is capable to raising viral
antigen-specific T cell immunity in mammals.
H7N9 VLP immunization induced HI, anti-NA, and anti-M1
humoral responses in chickens
To examine the immune-potentiating effect of the H7N9
VLPs in avian species, two-week-old SPF chickens were
administered with a primary and a booster vaccination of
10 μg of VLPs on day 0 and day 14 (Fig. 5a). To further
evaluate the VLPs’ effectiveness, an additional group of
chickens were inoculated with 10 μg of free antigens con-
sisting of HA, NA, and M1 at an 1:1:1 molar ratio for
comparison. A group administered with PBS was prepared
in parallel as control. Blood was collected on day 0, 14, 19,
26, and 40 to assess the serum HI titers. In experiments
using inactivated H7N9 virions as HA antigens, changes
in HI serum titers could be observed after day 14 (Fig. 5b).
Even though chickens receiving free proteins also showed
increased HI titers as compared to the PBS control, the
VLP-vaccinated group had significantly higher HI titers. A
low HI activity was observed for the PBS control. Over
the observation period, HI titers for both VLP and free
protein groups increased over time, reaching a peak at
173.33 and 83.33 respectively.
Anti-NA and anti-M1 titers in the serum of the vacci-
nated chickens were also quantified by ELISA with the
blood samples collected on day 26 post immunization. For
the anti-NA titer, immunization with free protein was
found to elevate the titer to a median value of 2,434,
whereas immunization with the VLP resulted in a median
titer of 3,957 (Fig. 5c). Similarly, VLP immunization elic-
ited higher anti-M1 titer (median = 685) as compared to
free protein immunization (median = 221) (Fig. 5d). The
experimental results confirm the presence of HA, NA,
and M1 on the VLPs. The VLPs’ are also demonstrated to
possess superior capability in eliciting antigen-specific
humoral responses as compared to free protein antigens.
H7N9 VLP elicited virus-specific T cell response in chickens
To analyze antigen-specific T cell responses in chick-
ens, chicken spleens were harvested on day 40 post
immunization. Following splenocyte isolation and
Fig. 2 Expression and characterization of H7N9 VLP. a The viral titers of
three recombinant baculoviruses were determined by plaque assay.
The titer of recombinant baculovirus-HA (rBac-HA) was approxmiately
6 × 106 PFU/ml (left), the rBac-NA 3 × 107 PFU/ml (center), and the
rBac-M1 1.1 × 108 PFU/ml (right). The protein expression of HA, NA, and
M1 was identified respectively by immunofluorescence assay (lower
panel). b Sf9 cells were co-infected with rBac-HA, rBac-NA, and rBac-M1
under various MOI combinations, and the VLPs were purified via
sucrose gradient centrifugation. Formulation derived from the
combinations of rBac-HA (MOI 2), rBac-NA (MOI 2), and rBac-M1
(MOI 2) co-infection exhibited the highest HA activity. c H7N9
VLP, H7/HA protein, N9/NA protein, and M1 proteins were detected by
Western blot
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stimulation with H7N9 VLPs, the splenocytes were
lysed and real-time RT-PCR was performed to quan-
tify IFN-γ and IL-4 mRNA expression levels (Fig. 6a
and b). It was observed that immunization with free
protein formulation and VLPs increased the IFN-γ





Fig. 3 The formation of VLP and proper antigen display of viral proteins were verified. a The HA (left) and NA (right) proteins were detected by
antibodies labeled with 6 nm gold under a transmission electron microscope. Scale bars = 50 nm. b Size distribution and (c) surface zeta potential
of the VLPs were analyzed using nanoparticle tracking analysis. Influenza virus A/PuertoRico/8/34(H1N1) was analyzed under the same settings as
a reference. d Hemagglutination activity of H7N9 VLPs was assessed by a hemagglutination assay. The total protein contents of H7N9 VLP are
indicated based on a two-fold serial dilution. PBS was included as the negative control
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and Th2-directed immune responses by both formula-
tions. Upon statistical analysis, however, only the
VLPs induced significantly higher IFN-γ and IL-4 ex-
pression, whereas enhancement by the free protein
formulation did not achieve statistical significance
owing to a high degree of variability. The results indi-
cate that the immune responses induced by the free
proteins can be highly variable. In contrast,
immunization with the VLPs facilitated a more con-
sistent and robust induction in both Th1 and Th2
responses.
CD4/CD8 ratio was also analyzed using flow cytomet-
ric analysis (Fig. 6c). On day 40 post immunization, VLP
immunization was shown to significantly increase the
CD4/CD8 ratio from a mean value of 0.56 to 0.64 (p =







Fig. 4 The immunogenicity of H7N9 VLP in a mouse model. a Mice (n = 6 per group) were immunized with VLPs (10 μg per mouse intramuscularly
on day 0 and 14) or PBS, and blood samples were collected. Mice receiving H7N9 VLPs showed significantly increased serum HI titer against the H7N9
inactivated virions (b) or H7N9 VLPs (c). Mice splenocytes were isolated on day 28 and restimulated ex vivo with the H7N9 VLPs. The antigen-specific
cytokine responses were detected by intracellular cytokine staining. Comparing with the PBS control, mice receiving the H7N9 VLPs showed elevated
CD4 IL-4 and CD8 TNF production (d, f), whereas the production of CD4 IFN-γ or CD8 IFN-γ revealed no statistical difference (e, g). Error bars are mean
± SEM. *p < 0.05, **p < 0.01, and ***p < 0.001
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formulation also increased the mean value of CD4/CD8
ratio, no statistical significant was observed (p = 0.31).
The results corroborate a more robust and consistent
immune response upon exposure to H7N9 virions fol-
lowing VLP immunization.
Discussion
Since the identification of the avian influenza A (H7N9)
infection in human in March 2013, the viral threat has
prompted a global effort to develop vaccine candidates
as humans have little immunity to this reassorted virus
[18–20]. This leap of the virus from birds to humans
was attributed to multiple reassortment events, and con-
tinuing reassortment events may lead to emergence of
more infective strains. Disease management at both the
human and animal levels are thus of major importance.
In this study, A/Taiwan/S02076/2013(H7N9), a strain
isolated in Taiwan [13], was used for the development of
a vaccine candidate through the preparation of VLPs.
Co-infection of recombinant baculoviruses in insect cells
yielded influenza A/H7N9 VLPs that coexpressed HA,
NA, and M1 proteins, which have molecular weights
consistent with previously published studies [10, 11].
The VLPs are monodisperse and contain approximately
Fig. 5 The immunogenicity of H7N9 VLP in a chicken model. a SPF chickens (n = 6 per group) were immunized with VLPs, HA/NA/M1 free proteins
(10 μg per chicken intramuscularly on day 0 and 14) or PBS, and blood samples were collected. b Chickens receiving H7N9 VLPs showed significantly
increased serum HI titer against the H7N9 inactivated virions. Error bars are mean ± SEM. c, d On day 26 post-immunization, chickens receiving VLPs
exhibited higher serum ELISA titers against purified NA and M1 proteins as compared to the PBS control. Lines and boxes represent upper extreme,
25th, 50th, 75th percentile, and lower extreme. *p < 0.05, **p < 0.01, and ***p < 0.001
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800 HA proteins per particles. These VLPs were found
to induce proper humoral and cellular immunity against
the H7N9 virus in animal models. In particular, the VLPs
were found to be superior in eliciting viral-antigen-
specific humoral and cellular immune responses as com-
pared to a free protein formulation in an avian model,
which has not been investigated previously.
VLPs are a versatile system that presents a compelling
alternative to conventional vaccine formulations as they
possess the morphological semblance to natural viral
particles. In the present study we applied nanoparticle
tracking analysis and transmission electron microscopy
to validate the structure and antigenicity of the VLPs.
These analyses showed virus-like features consistent
with other VLP formulations reported in previous stud-
ies [6, 10, 11, 21]. It is worth noting that although an Sf9
insect cell system was adopted for the production of the
H7N9 VLPs in this study, the VLP platform is highly
versatile and may be produced using other culture sys-
tems. For instance, a previous study by Chang et al.
employed an alternate High Five insect cell culture sys-
tem for VLP production [22, 23], demonstrating high
production yield upon High Five system optimization. In
the present study, we showed that varying the MOI of
the different recombinant baculoviruses impacted the
VLP production, offering information toward further
optimization of the Sf9 system for VLP generation.
We first validated the potency of the VLPs in a mouse
model. Given that neutralizing antibodies against the
globular head of hemagglutinin protein are the primary
mediators of most vaccine-induced protection against
influenza, a hemagglutination inhibition assay was used
to examine the VLPs as a vaccine candidate against
H7N9. An HI antibody titer of 1:40 is the accepted cor-
relate of protection for human HA split inactivated
vaccines [24]. Immunization with the VLPs resulted in a
mouse serum HI titer of 1:160 against the H7N9 virions.
Although future animal studies with viral challenges are
warranted, the present result validates the immunopo-
tentiation effect of our VLPs, which is on par with those
in previous reports.
Despite previous studies that examined different formu-
lations of H7N9 VLPs in mouse models [9–11, 25, 26], no
examination of H7N9 vaccination in avian models has
been reported to the best of our knowledge. Given that
the management of the avian influenza virus would benefit
from both human and poultry vaccinations, we investi-
gated the VLPs’ vaccination effect in SPF chickens. As
compared to a free protein formulation, the VLP vaccin-
ation yielded increased HI serum titers, anti-NA titers,
and anti-M1 titers. It is also worth noting that upon exam-
ination of cellular immune responses, we observed that
the VLP immunization resulted in elevated splenic IFN-γ
and IL-4 upon subsequent viral exposure. The cellular
immune responses elicited by VLPs in SPF chickens are
consistent with previous studies examining VLP immuni-
zations in other animal models [21].
In the present study, we purified our VLPs and made
sure that no detectable baculovirus titer was present in
any of our batches. The purification is critical as residual
baculoviral proteins were previously shown to trigger in-
nate immune responses through TLR9 and other pattern
recognition receptors [27, 28]. Towards future clinical
translation, the elimination of residual baculovirus con-
tamination is of high importance.
Even though the free protein formulation, which is a
mixture consisting of free HA, NA, and M1 proteins at
a 1:1:1 ratio, also elicited humoral and cellular responses
in our study, the responses were either weaker or more
variable as compared to those elicited by the VLPs. The
a b c
Fig. 6 Cell-mediated immunity response induced by H7N9 VLP in chickens (n = 6 per group). Splenocytes isolated from chickens on day 40 after
immunization were stimulated ex vivo with H7N9 VLPs, and the cell-mediated response was evaluated. a Splenic IFN-γ and (b) IL-4 mRNA levels
were investigated using real-time PCR. By using flow cytometry, chickens receiving VLPs exhibit significantly higher ratio of splenic CD4+ / CD8+
cell count (c), indicating stronger T helper cell response induced by H7N9 VLP vaccination. Error bars are mean ± SEM. *p < 0.05, **p < 0.01,
and ***p < 0.001
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finding fortifies the notion that the H7N9 VLPs may
serve as a compelling vaccine candidate in poultry farm-
ing, which typically employs inactivated or subunit vac-
cines for disease management [29–31].
Conclusions
Our study has prepared H7N9 VLPs co-expressing HA,
NA, and M1 as a vaccine candidate against avian influ-
enza. The platform elicited more potent humoral im-
mune responses and more consistent cellular immune
responses as compared to the free protein formulation.
Although future studies involving viral challenges are
warranted, the platform presents a viable candidate for
avian influenza management in both human and animal
settings.
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